Ms. Es Sabar commented, “I feel very fortunate to have had the opportunity to help build one of the world’s leading translational centres here in Canada. We have established a unique network of partnerships across academia, industry, government, foundations and fellow translational centres; a substantial financial runway; a fully integrated incubator (CDRD) with an accelerator (CDRD Ventures); and a robust technology pipeline that will continue to generate valuable commercial transactions. Given this solid foundation, I feel it is an opportune time for me to devote my passion and energy to new opportunities around global innovation and translation.”
CDRD Chair, Dawn Svoronos commented, “Karimah has played a profoundly important role in creating the vision and conditions for CDRD’s success, and in bringing the organization to international prominence. Her contributions to CDRD and the broader life sciences and research innovation community in British Columbia, Canada and globally have been immeasurable.” Svoronos continued, “On behalf of the entire CDRD management and Board, I would like to extend a heartfelt thank you and best wishes to Karimah.”
Es Sabar added, “It has been a tremendous honour to work with a remarkable scientific and commercial team. I am proud of what we have collectively accomplished, and confident that CDRD is well-poised for a long and successful future as a high performing and impactful commercialization engine.”
Svoronos also indicated that CDRD Vice-Chair Gordon C. McCauley, a Vancouver-based life sciences executive with global experience in the industry, will assume the position of interim CEO in addition to his current business responsibilities. Mr. McCauley and Ms. Es Sabar are committed to ensuring a smooth leadership transition and that all operational activities continue seamlessly.
CDRD is Canada’s fully-integrated national drug development and commercialization centre, providing expertise and infrastructure to enable researchers from leading health research institutions to advance promising early-stage drug candidates. CDRD works in partnership with academia, industry, government and foundations, to identify and de-risk promising discoveries, and transform them into commercially viable investment opportunities for the private sector — thus successfully bridging commercialization gaps between academia and industry, and translating research discoveries into new therapies for patients. Canada’s Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR). www.cdrd.ca For more information: Gordon C. McCauley Interim CEO, CDRD email@example.com 604-218-4742.
For more information:
Gordon C. McCauley Interim CEO, CDRD